Abstract
"Cancer-germline" genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of cancer patients. MAGE-6 is expressed in more than 70% of metastatic melanomas and more than 50% of carcinomas of the lung, esophagus, bladder, and head and neck. We report here the identification of a new MAGE-6 antigenic peptide, which is recognized by a tumor-specific cytolytic T lymphocyte clone isolated from a melanoma patient. The peptide, ISGGPRISY, corresponds to positions 293 to 301 of the MAGE-6 protein sequence and is presented by HLA-Cw1601 molecules.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / immunology*
-
COS Cells
-
Cell Line, Tumor
-
Cytotoxicity, Immunologic / drug effects
-
Cytotoxicity, Immunologic / immunology
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Melanoma / immunology
-
Melanoma / pathology
-
Melanoma-Specific Antigens
-
Molecular Sequence Data
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / immunology*
-
Oligopeptides / genetics
-
Oligopeptides / immunology
-
Oligopeptides / pharmacology
-
T-Lymphocytes, Cytotoxic / immunology*
Substances
-
Antigens, Neoplasm
-
MAGEA1 protein, human
-
MAGEA6 protein, human
-
Melanoma-Specific Antigens
-
Neoplasm Proteins
-
Oligopeptides